Jeremy Skillington
Chief Executive Officer bei POOLBEG PHARMA PLC
Vermögen: 108 689 $ am 31.03.2024
Profil
Jeremy Skillington is the founder and Chief Executive Officer of TriMod Therapeutics Ltd.
which is founded in 2011.
He is currently the Chief Executive Officer & Executive Director at Poolbeg Pharma Plc since 2021.
Previously, he worked as a Senior Director-Business Development at Opsona Therapeutics Ltd.
from 2009 to 2010.
He also worked as a Senior Manager-Business Development at Genentech, Inc. and as a Principal at Academia, Inc. Dr. Skillington completed his undergraduate and doctorate degrees from the National University of Ireland.
Bekannte Unternehmensbeteiligungen
| Unternehmen | Datum | Anzahl der Aktien | Bewertung | Datum der Bewertung |
|---|---|---|---|---|
POOLBEG PHARMA PLC
0,17% | 21.02.2024 | 873 497 ( 0,17% ) | 108 689 $ | 31.03.2024 |
Aktive Positionen von Jeremy Skillington
| Unternehmen | Position | Beginn |
|---|---|---|
| POOLBEG PHARMA PLC | Chief Executive Officer | 01.05.2021 |
TriMod Therapeutics Ltd.
 TriMod Therapeutics Ltd. BiotechnologyHealth Technology TriMod Therapeutics Ltd develops novel platform technologies to treat cancer and autoimmune diseases. It offers TriMoVac technology that enhances the patients' immune response to the tumour and promotes its eradication by attenuating its' immune subversion strategies. The company was founded by Kingston Mills and Jeremy Skillingtonand in 2011 is headquartered in Dublin, Ireland. | Chief Executive Officer | 01.01.2011 |
Ehemalige bekannte Positionen von Jeremy Skillington
| Unternehmen | Position | Ende |
|---|---|---|
Opsona Therapeutics Ltd.
 Opsona Therapeutics Ltd. Pharmaceuticals: MajorHealth Technology Opsona Therapeutics Ltd. operates as a immunology drug development company. It focuses on novel therapeutics and specializes in the prevention and treatment of solid organ transplantation, cancer, diabetes, autoimmune, inflammatory and Alzheimer’s diseases. The firm developed OPN-305, an antibody to reduce pro-inflammatory cytokine production, which is now at the clinical testing phase. The company was founded by Luke O'Neill, Kingston Mills and Dermot Kelleher in 2004 and is headquartered Dublin, Ireland. | Corporate Officer/Principal | 01.11.2010 |
Academia, Inc.
 Academia, Inc. Internet Software/ServicesTechnology Services Academia, Inc. develops and provides social sharing platform for academic researchers. Its platform enables researchers to share their research, monitor deep analytics, and track the research of academics they follow. The company was founded by Richard Price in September 2008 and is headquartered in San Francisco, CA. | Corporate Officer/Principal | - |
Genentech, Inc.
 Genentech, Inc. BiotechnologyHealth Technology Genentech, Inc. develops, manufactures and markets pharmaceutical products for life-threatening medical conditions. It studies various areas including oncology, immunology, neuroscience, ophthalmic diseases, microbial pathogenesis, metabolic diseases, cardiovascular diseases, and opportunistic areas. The company was founded by Herb W. Boyer and Robert A. Swanson in 1976 and is headquartered in South San Francisco, CA. | Corporate Officer/Principal | - |
Ausbildung von Jeremy Skillington
| National University of Ireland | Doctorate Degree |
Erfahrungen
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Beziehungen
Beziehungen ersten Grades
Unternehmen ersten Grades
Herr
Frau
Aufsichtsräte
Führungskräfte
Unternehmensverbindungen
| Börsennotierte Unternehmen | 1 |
|---|---|
| POOLBEG PHARMA PLC | Health Technology |
| Private Unternehmen | 4 |
|---|---|
Genentech, Inc.
Genentech, Inc. BiotechnologyHealth Technology Genentech, Inc. develops, manufactures and markets pharmaceutical products for life-threatening medical conditions. It studies various areas including oncology, immunology, neuroscience, ophthalmic diseases, microbial pathogenesis, metabolic diseases, cardiovascular diseases, and opportunistic areas. The company was founded by Herb W. Boyer and Robert A. Swanson in 1976 and is headquartered in South San Francisco, CA. | Health Technology |
Opsona Therapeutics Ltd.
Opsona Therapeutics Ltd. Pharmaceuticals: MajorHealth Technology Opsona Therapeutics Ltd. operates as a immunology drug development company. It focuses on novel therapeutics and specializes in the prevention and treatment of solid organ transplantation, cancer, diabetes, autoimmune, inflammatory and Alzheimer’s diseases. The firm developed OPN-305, an antibody to reduce pro-inflammatory cytokine production, which is now at the clinical testing phase. The company was founded by Luke O'Neill, Kingston Mills and Dermot Kelleher in 2004 and is headquartered Dublin, Ireland. | Health Technology |
Academia, Inc.
Academia, Inc. Internet Software/ServicesTechnology Services Academia, Inc. develops and provides social sharing platform for academic researchers. Its platform enables researchers to share their research, monitor deep analytics, and track the research of academics they follow. The company was founded by Richard Price in September 2008 and is headquartered in San Francisco, CA. | Technology Services |
TriMod Therapeutics Ltd.
TriMod Therapeutics Ltd. BiotechnologyHealth Technology TriMod Therapeutics Ltd develops novel platform technologies to treat cancer and autoimmune diseases. It offers TriMoVac technology that enhances the patients' immune response to the tumour and promotes its eradication by attenuating its' immune subversion strategies. The company was founded by Kingston Mills and Jeremy Skillingtonand in 2011 is headquartered in Dublin, Ireland. | Health Technology |
